EU-AMRI endorses the “Porto Declaration on Cancer Research”, calling for further European-wide deployment of high-quality infrastructures.

On 3 May 2021, following the Cancer Research Summit 2021, hosted by the Portuguese Presidency of the European Council, the Porto Declaration on Cancer Research was published as an open call for collective action towards a comprehensive translational cancer research approach focused on personalised and precision medicine and covering the entire cancer research continuum, from prevention to care.

EU-AMRI is the strategic European Alliance of Medical Research Infrastructures formed by three patient-driven and disease-agnostic European infrastructures, each founded by Member States in 2014: BBMRI for Biobanking and Biomolecular Resources, EATRIS for Translational Research, and ECRIN for multinational Clinical Trials.

Together, they facilitate the access to high-quality scientific services and facilities, including those of Comprehensive Cancer Centres (CCCs), as well as multidisciplinary expertise within the research community for the seamless translation of their research into patient benefit.

EU-AMRI has endorsed the Porto Declaration and welcomes its emphasis on the critical need to strengthen high quality networked infrastructures for translational research, clinical research and outcomes research, as one of the key success factors of the future Cancer Mission and Europe’s Beating Cancer Plan. As considerable resources will be dedicated to the fight against cancer at national and European level, building on the existing national investments in well-developed and interconnected infrastructures should indeed be prioritised by the European Commission and member states to truly unlock the societal benefits of European research and innovation.

The decisive role that CCCs along with university hospitals will play in supporting the Cancer Mission’s objectives is undeniable. In addition, EU-AMRI calls for a new level of mobilisation and cooperation with already established and European wide distributed research infrastructures, such as EU-AMRI members, to effectively provide researchers with access to the critical mass of services they require and to deliver on the promises of the Mission: inter-disciplinary and cross-institutional coordination.

We invite the members of our infrastructures to endorse the Porto Declaration on Cancer Research and we look forward to continuing our dialogue with all relevant stakeholders to set the Cancer Mission and Europe’s Beating Cancer Plan for success and to save the lives of European citizens.

---

1 In September 2020, BBMRI, EATRIS, ECRIN and ELIXIR provided a detailed overview of what their infrastructures could do to support the Cancer mission and the European cancer research community. Read more here.
**BBMRI-ERIC** is the European Research Infrastructure for biobanking and biomolecular resources that brings together all the main players from the biobanking field (clinicians, patient advocacy & public, researchers, biobankers, and industry) to boost biomedical research. BBMRI offers quality management services, support with ethical, legal and societal issues, and a number of online tools and software solutions for biobankers and researchers. Ultimately, the goal of BBMRI is to make new treatments possible. Hosting one of the world’s largest catalogues of human biosamples (tissues, liquid biopsies, and cells as well as analytes thereof such as DNA, RNA, Proteins etc.) and associated clinical and research data, BBMRI-ERIC connects more than 600 biobanks from 20 EU countries and 1 international organization. Its mission is to facilitate research on human samples and data for personalised medicine, while keeping the highest scientific standards and, most importantly, preserving patients and citizens’ privacy. BBMRI-ERIC provides services to academia and industry to develop better treatments, test diagnostic tools and advance biomedical research. BBMRI-ERIC is composed of 21 national nodes that support biobanking at the local level, and a European headquarter based in Graz, Austria.

**EATRIS** is the European Research Infrastructure for Translational Medicine that aims to accelerate the translation of biomedical discoveries into patient benefit. EATRIS helps academia and industry decrease risk to their drug, vaccine or diagnostic development programme and increase their potential to reach patients. EATRIS provides fast, tailored access to cutting-edge enabling technologies and expertise in translational research, focusing on preclinical and early clinical development of drugs, vaccines and diagnostics. Via our central hub in Amsterdam, users can access the vast array of clinical expertise and high-end facilities that are available within 110+ top-tier academic centres across 14 European countries. Solutions are provided in the fields of advanced therapy medicinal products, biomarkers, imaging and tracing, small molecules and vaccines.

**ECRIN** is the European Clinical Research Infrastructure Network, a public, non-profit organisation that provides expertise in clinical trial preparation, setup, and management, representing 12 European countries, over 350 million citizens, and dozens of multinational clinical trials. ECRIN offers researchers support to prepare and implement multinational trials. Support areas include advice, preparation of applications for funding, protocol evaluation, trial management, quality assurance and more. ECRIN offers investigators the tools they need to address regulatory and ethical issues, to measure outcomes and to assess risk. These tools are critical for project success, especially when operating in a multicountry context where local legislation and requirements can vary greatly. ECRIN provides consultancy and management services to dozens of multinational trials, with an average of seven countries per trial.